TY - JOUR
T1 - CD97 is a critical regulator of acute myeloid leukemia stem cell function
AU - Martin, Gaëlle H.
AU - Roy, Nainita
AU - Chakraborty, Sohini
AU - Desrichard, Alexis
AU - Chung, Stephen S.
AU - Woolthuis, Carolien M.
AU - Hu, Wenhuo
AU - Berezniuk, Iryna
AU - Garrett-Bakelman, Francine E.
AU - Hamann, Jörg
AU - Devlin, Sean M.
AU - Chan, Timothy A.
AU - Park, Christopher Y.
PY - 2019/10/7
Y1 - 2019/10/7
N2 - Despite significant efforts to improve therapies for acute myeloid leukemia (AML), clinical outcomes remain poor. Understanding the mechanisms that regulate the development and maintenance of leukemic stem cells (LSCs) is important to reveal new therapeutic opportunities. We have identified CD97, a member of the adhesion class of G protein-coupled receptors (GPCRs), as a frequently up-regulated antigen on AML blasts that is a critical regulator of blast function. High levels of CD97 correlate with poor prognosis, and silencing of CD97 reduces disease aggressiveness in vivo. These phenotypes are due to CD97's ability to promote proliferation, survival, and the maintenance of the undifferentiated state in leukemic blasts. Collectively, our data credential CD97 as a promising therapeutic target on LSCs in AML.
AB - Despite significant efforts to improve therapies for acute myeloid leukemia (AML), clinical outcomes remain poor. Understanding the mechanisms that regulate the development and maintenance of leukemic stem cells (LSCs) is important to reveal new therapeutic opportunities. We have identified CD97, a member of the adhesion class of G protein-coupled receptors (GPCRs), as a frequently up-regulated antigen on AML blasts that is a critical regulator of blast function. High levels of CD97 correlate with poor prognosis, and silencing of CD97 reduces disease aggressiveness in vivo. These phenotypes are due to CD97's ability to promote proliferation, survival, and the maintenance of the undifferentiated state in leukemic blasts. Collectively, our data credential CD97 as a promising therapeutic target on LSCs in AML.
UR - http://www.scopus.com/inward/record.url?scp=85072994376&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85072994376&partnerID=8YFLogxK
U2 - 10.1084/jem.20190598
DO - 10.1084/jem.20190598
M3 - Article
C2 - 31371381
SN - 0022-1007
VL - 216
SP - 2362
EP - 2377
JO - The Journal of experimental medicine
JF - The Journal of experimental medicine
IS - 10
ER -